Search Tag: Bladder Cancer
2025 22 May
Lymphovascular invasion (LVI) is a critical prognostic marker in urothelial carcinoma of the bladder (UCB), associated with increased tumour aggressiveness, recurrence and lower survival rates. Conventionally, the presence of LVI is confirmed through immunohistochemical (IHC) staining, a method that, while accurate, is both time-consuming and...Read more
2025 29 Jan
Bladder cancer (BCa) is one of the most common malignancies affecting the urinary tract. It requires careful histological grading, as treatment strategies differ significantly between low- and high-grade cases. High-grade BCa often carries a greater risk of recurrence and progression to muscle-invasive disease, while low-grade tumours tend to...Read more
2024 08 Sep
Bladder cancer (BCa) is one of the most prevalent malignancies of the urinary system. A crucial distinction in BCa is whether it is muscle-invasive (MIBC) or non-muscle-invasive (NMIBC), as this classification significantly impacts treatment strategies and patient outcomes. Currently, invasive biopsy procedures and magnetic resonance imaging (MRI)...Read more
2024 03 Apr
<marquee behavior="slide" direction="left" scrollamount="30" style="text-align: center;"> <font color=#ff6600> Find ESMO On Social Media </marquee> Read more
2022 25 Apr
A small multisite study recently showed that artificial intelligence (AI) improved the ability of physicians to determine whether bladder cancer patients responded to chemotherapy before a radical cystectomy. Establishing whether bladder cancer patients show a complete response to chemotherapy is important for determining whether the bladder...Read more
2020 21 Apr
A research predicts a decline in cancer mortality rates in 2020 in the EU. However, due to the COVID-19 pandemic cancer patient safety is compromised, but can still be improved with certain policies. You may also like : Prostate is Now Most Common Cancer Cancer in the EU Total cancer mortality rates in the...Read more